Delayed autoimmune hemolytic anemia in efalizumab-treated psoriasis

Journal of the American Academy of Dermatology

Volumn 58, Issue 6, 2008, Pages 1053-1055

  Kwan, Julia M ^a   Reese, Amy M ^a   Trafeli, John P ^b  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^b Space and Naval Warfare Systems Center Pacific   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIPOTRIOL; EFALIZUMAB; METHOTREXATE; PIMECROLIMUS; PREDNISONE; STEROID; TAZAROTENE;

ADULT; ANAMNESIS; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD CELL COUNT; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG WITHDRAWAL; HUMAN; LABORATORY TEST; LOADING DRUG DOSE; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSORIASIS;

ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANTIBODIES, MONOCLONAL; CELL MIGRATION INHIBITION; HUMANS; MALE; MIDDLE AGED; PSORIASIS;

EID: 43249128261     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2008.01.021     Document Type: Article

References (12)

1. Stern D.K., Tripp J.M., Ho V.C., and Lebwohl M. The use of systemic immune moderators in dermatology: an update. Dermatol Clin 23 (2005) 259-300
2. Weinberg J.M., Bottino C.J., Lindholm J., and Buchholz R. Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept. J Drugs Dermatol 4 (2005) 544-556
3. Gordon K.B., Papp K.A., Hamilton T.K., Walicke P.A., Dummer W., Li N., et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 290 (2003) 3073-3080
4. Lebwohl M., Tyring S.K., Hamilton T.K., Toth D., Glazer S., Tawfik N.H., et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 349 (2003) 2004-2013
5. Leonardi C.L., Papp K.A., Gordon K.B., Menter A., Feldman S.R., Caro I., et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 52 (2005) 425-433
6. Menter A., Gordon K., Carey W., Hamilton T., Glazer S., Caro I., et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 141 (2005) 31-38
7. Ortonne J.P., Shear N., Shumack S., and Henninger E. CLEAR Multinational Study Group. Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial. BMC Dermatol 5 (2005) 13
8. Gottlieb A.B., Hamilton T., Caro I., Kwon P., Compton P.G., and Leonardi C.L. Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from on ongoing trial. J Am Acad Dermatol 54 Suppl (2006) S154-S163
9. Warkentin T.E., and Kwon P. Immune thrombocytopenia associated with efalizumab therapy for psoriasis. Ann Intern Med 143 (2005) 761-763
10. Scheinfeld N. Efalizumab: a review of events reported during clinical trials and side effects. Expert Opin Drug Saf 5 (2006) 197-209
11. Raptiva. [efalizumab] [package insert] (2005), Genentech Inc, South San Francisco (CA)
12. Tom W.L., Miller M.D., Hurley M.Y., Suneja T., Kudva G., Leonardi C.L., et al. Efalizumab-induced autoimmune pancytopenia. Br J Dermatol 155 (2006) 1045-1047